Chloroquine efficacy for Plasmodium vivax in Myanmar in populations with high genetic diversity and moderate parasite gene flow.
<p><strong>BACKGROUND:</strong><em>Plasmodium vivax</em> malaria remains a major public health burden in Myanmar. Resistance to chloroquine (CQ), the first-line treatment for <em>P. vivax</em>, has been reported in the country and has potential to undermine...
Prif Awduron: | Htun, M, Mon, N, Aye, K, Hlaing, C, Kyaw, M, Handayuni, I, Trimarsanto, H, Bustos, D, Ringwald, P, Price, R, Auburn, S, Thriemer, K |
---|---|
Fformat: | Journal article |
Iaith: | English |
Cyhoeddwyd: |
BioMed Central
2017
|
Eitemau Tebyg
-
Where chloroquine still works: the genetic make-up and susceptibility of Plasmodium vivax to chloroquine plus primaquine in Bhutan
gan: Wangchuk, S, et al.
Cyhoeddwyd: (2016) -
Chloroquine efficacy for Plasmodium vivax malaria treatment in southern Ethiopia
gan: Getachew, S, et al.
Cyhoeddwyd: (2015) -
Plasmodium vivax resistance to chloroquine in Dawei, southern Myanmar.
gan: Guthmann, J, et al.
Cyhoeddwyd: (2008) -
Plasmodium vivax trophozoites insensitive to chloroquine.
gan: Sharrock, W, et al.
Cyhoeddwyd: (2008) -
Therapeutic Responses of Plasmodium vivax Malaria to Chloroquine and Primaquine Treatment in Northeastern Myanmar.
gan: Yuan, L, et al.
Cyhoeddwyd: (2014)